LB4330
LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.
Overview
LB4330 is a fusion protein developed by L & L Bio, Ningbo, China. Its target is Claudin 18.2 (the sponsor names Claudin18.2 x IL-10). The sponsor states: Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"LB4330" OR ABSTRACT:"LB4330") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LB4330, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTAC01-CLDN18.2
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentBDC-4182
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentLB1410
Shares Hutchmed and the tags pipeline, ctgov-ingest.
- TreatmentHMPL-760
Shares Hutchmed and the tags pipeline, ctgov-ingest.
- TreatmentRC118-ADC
Shares Claudin 18.2 and the tags pipeline, ctgov-ingest.
- TreatmentIAH0968
Shares Hutchmed and the tags pipeline, ctgov-ingest.
- TreatmentHMPL-306
Shares Hutchmed and the tags pipeline, ctgov-ingest.
- TreatmentHMPL-453
Shares Hutchmed and the tags pipeline, ctgov-ingest.